AI Engines For more Details: Perplexity Kagi Labs You
Antineoplastic Activity: Cytarabine belongs to a class of medications known as antimetabolites, which work by interfering with DNA synthesis and inhibiting the growth and replication of cancer cells. Cytarabine is a nucleoside analog that is incorporated into DNA during the S-phase of the cell cycle, leading to DNA strand breaks and inhibition of DNA synthesis. This ultimately results in cell cycle arrest and apoptosis (programmed cell death) of cancer cells.
Treatment of Acute Myeloid Leukemia (AML): Cytarabine is a cornerstone of induction chemotherapy regimens for the treatment of newly diagnosed acute myeloid leukemia (AML), a type of blood cancer characterized by the rapid proliferation of immature myeloid cells in the bone marrow. Cytarabine is often used in combination with other chemotherapy drugs such as anthracyclines (e.g., daunorubicin) or cytarabine plus anthracycline-based regimens (e.g., "7+3" regimen) to induce remission and achieve a complete response in patients with AML.
Treatment of Acute Lymphoblastic Leukemia (ALL): Cytarabine may also be used in the treatment of acute lymphoblastic leukemia (ALL), a type of blood cancer that affects lymphoid cells. It is often used in combination with other chemotherapy agents as part of induction, consolidation, or maintenance therapy regimens for ALL, particularly in pediatric patients. Cytarabine-based chemotherapy regimens help to eradicate leukemic cells from the bone marrow and achieve long-term remission in patients with ALL.
Treatment of Non-Hodgkin's Lymphoma (NHL): Cytarabine may be used in the treatment of certain types of non-Hodgkin's lymphoma (NHL), particularly aggressive subtypes such as diffuse large B-cell lymphoma (DLBCL) or Burkitt lymphoma. It may be used as part of combination chemotherapy regimens to induce remission, reduce tumor burden, and improve survival outcomes in patients with NHL.
Dosage and Administration: Cytarabine is typically administered intravenously (IV) or subcutaneously (SC) by a healthcare professional in a hospital or clinic setting. The dosage and schedule of administration depend on factors such as the type of cancer being treated, the patient's overall health, and their response to treatment. Cytarabine is often given in cycles, with rest periods between doses to allow the body to recover from side effects.
Side Effects: Common side effects of cytarabine may include nausea, vomiting, diarrhea, mucositis (inflammation of the mucous membranes), bone marrow suppression (resulting in low blood cell counts), hair loss, fatigue, and increased risk of infection. Cytarabine can also cause neurotoxicity, particularly at high doses or with prolonged use, leading to neurological symptoms such as headache, confusion, seizures, and cerebellar dysfunction.
Long-term Effects: Cytarabine treatment may be associated with long-term effects such as increased risk of secondary malignancies, particularly therapy-related myeloid neoplasms (t-MN) or myelodysplastic syndromes (MDS), as well as infertility and reproductive toxicities. Patients should be informed about the potential long-term effects of cytarabine therapy and may require long-term monitoring for late-onset complications.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Blautia | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | -0.3 | |
| ADHD | 1.3 | 1.3 | |
| Allergic Rhinitis (Hay Fever) | 1.3 | 1.3 | 0 |
| Allergies | 1.5 | 2.3 | -0.53 |
| Allergy to milk products | 0.9 | 0.6 | 0.5 |
| Alopecia (Hair Loss) | 0.1 | 0.1 | |
| Alzheimer's disease | 2.2 | 1.6 | 0.38 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.4 | 0.6 | 1.33 |
| Ankylosing spondylitis | 1 | 1.2 | -0.2 |
| Anorexia Nervosa | 0.4 | 0.7 | -0.75 |
| Asthma | 1.4 | 2 | -0.43 |
| Atherosclerosis | 1.1 | 0.3 | 2.67 |
| Atrial fibrillation | 1 | 0.6 | 0.67 |
| Autism | 3.4 | 2.8 | 0.21 |
| Autoimmune Disease | 0.3 | 0.3 | 0 |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.7 | 0.7 | |
| Bipolar Disorder | 0.3 | 0.3 | |
| Brain Trauma | 0.3 | 0.6 | -1 |
| Breast Cancer | 0.1 | 0.1 | |
| Cancer (General) | 0.3 | 1.1 | -2.67 |
| Carcinoma | 1.1 | 0.7 | 0.57 |
| Celiac Disease | 0.5 | 1.1 | -1.2 |
| Cerebral Palsy | 0.9 | 0.4 | 1.25 |
| Chronic Fatigue Syndrome | 1.6 | 0.7 | 1.29 |
| Chronic Kidney Disease | 1.6 | 0.9 | 0.78 |
| Chronic Lyme | 0.1 | 0.3 | -2 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.3 | 0 |
| Chronic Urticaria (Hives) | 0.8 | -0.8 | |
| Coagulation / Micro clot triggering bacteria | 0.1 | -0.1 | |
| Cognitive Function | 0.6 | 0.3 | 1 |
| Colorectal Cancer | 2.5 | 0.6 | 3.17 |
| Constipation | 0.3 | 0.1 | 2 |
| Coronary artery disease | 0.6 | 0.7 | -0.17 |
| COVID-19 | 2.9 | 3.4 | -0.17 |
| Crohn's Disease | 2.2 | 2.1 | 0.05 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1.3 | -1.3 | |
| deep vein thrombosis | 0.6 | 0.3 | 1 |
| Denture Wearers Oral Shifts | 0.1 | 0.1 | |
| Depression | 3 | 2.4 | 0.25 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 0.9 | 1.1 | -0.22 |
| Endometriosis | 0.7 | 0.7 | |
| Eosinophilic Esophagitis | 0.3 | 0.3 | |
| Epilepsy | 1.5 | 1.6 | -0.07 |
| erectile dysfunction | 0.6 | 0.3 | 1 |
| Fibromyalgia | 1 | 0.6 | 0.67 |
| Functional constipation / chronic idiopathic constipation | 1 | 1.6 | -0.6 |
| gallstone disease (gsd) | 1 | 0.9 | 0.11 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | 0.1 | 5 |
| Generalized anxiety disorder | 1.6 | 1 | 0.6 |
| Gout | 0.6 | 0.3 | 1 |
| Graves' disease | 0.6 | 0.7 | -0.17 |
| Gulf War Syndrome | 0.1 | 1.4 | -13 |
| Halitosis | 0.7 | 0.7 | |
| Hashimoto's thyroiditis | 2.1 | 1.5 | 0.4 |
| Heart Failure | 1.1 | 0.7 | 0.57 |
| hemorrhagic stroke | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.3 | -0.3 | |
| hypercholesterolemia (High Cholesterol) | 0.6 | -0.6 | |
| hyperglycemia | 0.6 | 1.6 | -1.67 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.6 | |
| hypersomnia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 2.2 | 1.9 | 0.16 |
| Hypothyroidism | 0.3 | 0.4 | -0.33 |
| Hypoxia | 0.9 | 0.3 | 2 |
| IgA nephropathy (IgAN) | 0.6 | 0.9 | -0.5 |
| Inflammatory Bowel Disease | 2.8 | 2.9 | -0.04 |
| Insomnia | 0.4 | 1.3 | -2.25 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.7 | 0.7 | |
| Irritable Bowel Syndrome | 3.1 | 1.4 | 1.21 |
| ischemic stroke | 0.8 | 0.3 | 1.67 |
| Liver Cirrhosis | 1.5 | 2.3 | -0.53 |
| Long COVID | 2.5 | 2 | 0.25 |
| Lung Cancer | 0.7 | -0.7 | |
| Mast Cell Issues / mastitis | 0.1 | 0.3 | -2 |
| ME/CFS with IBS | 0.7 | -0.7 | |
| ME/CFS without IBS | 0.6 | 0.6 | 0 |
| Menopause | 0.7 | 0.3 | 1.33 |
| Metabolic Syndrome | 2.1 | 3.2 | -0.52 |
| Mood Disorders | 3.5 | 1.8 | 0.94 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.1 | 2 |
| Multiple Sclerosis | 1.7 | 1 | 0.7 |
| Multiple system atrophy (MSA) | 0.9 | 0.4 | 1.25 |
| neuropathic pain | 0.9 | -0.9 | |
| Neuropathy (all types) | 0.4 | 0.4 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.3 | 2.3 | -0.77 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
| Obesity | 4 | 4.6 | -0.15 |
| obsessive-compulsive disorder | 0.7 | 2.5 | -2.57 |
| Osteoarthritis | 1.6 | 0.9 | 0.78 |
| Osteoporosis | 0.3 | 1 | -2.33 |
| pancreatic cancer | 0.1 | 0.1 | |
| Parkinson's Disease | 3.1 | 2.4 | 0.29 |
| Polycystic ovary syndrome | 1.9 | 1 | 0.9 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.4 | 0.4 | |
| primary biliary cholangitis | 0.3 | -0.3 | |
| Primary sclerosing cholangitis | 0.6 | 0.8 | -0.33 |
| Psoriasis | 1 | 0.9 | 0.11 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.8 | 1.2 | 0.5 |
| Rosacea | 0.9 | 0.9 | |
| Schizophrenia | 2.3 | 1 | 1.3 |
| Sjögren syndrome | 0.1 | 1.3 | -12 |
| Sleep Apnea | 0.7 | 0.4 | 0.75 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.1 | 5 |
| Stress / posttraumatic stress disorder | 1.2 | 1.2 | 0 |
| Systemic Lupus Erythematosus | 1.6 | 0.9 | 0.78 |
| Tic Disorder | 0.3 | -0.3 | |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 1.3 | 1.6 | -0.23 |
| Type 2 Diabetes | 2.1 | 3 | -0.43 |
| Ulcerative colitis | 1.7 | 1.8 | -0.06 |
| Unhealthy Ageing | 2.2 | 0.6 | 2.67 |
| Vitiligo | 0.8 | 0.6 | 0.33 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
